Clinical trials: Restless Leg Syndrome
Restless Legs Syndrome
Transdermal Lisuride: a Trial for the Treatment of Patients With Restless Legs Syndrome (RLS)
The objective of this trial is to compare an individually optimized dose of the lisuride TTS patch against placebo and against an individually optimized dose of oral ropinirole (active- and placebo-controlled design) in…
- Trial name
- NCT00367822
- Testing
- Lisuride, Ropinirole
- Where
- Germany
- Volunteers
- 300 people
- Sponsor
- Axxonis Pharma AG
Restless Legs Syndrome
Dose Finding Study of Pramipexole (Sifrol) in Patients With Idiopathic Restless Legs Syndrome (RLS)
The purpose of this study was to evaluate the efficacy and safety of different doses of pramipexole (Sifrol) on subjective and objective symptoms of idiopathic Restless Legs Syndrome (RLS) and also to determine the optimal dose…
- Trial name
- NCT00239486
- Testing
- Pramipexole
- Where
- Finland
- Volunteers
- 109 people
- Sponsor
- Boehringer Ingelheim
Restless Legs Syndrome
Efficacy and Safety of Pramipexole Compared to Placebo in the Treatment of Restless Legs Syndrome (RLS)
A 12 week clinical trial was conducted in the United States in order to compare pramipexole (Mirapex®) versus placebo for the ability to reduce the symptoms of restless legs syndrome in adult subjects.
- Trial name
- NCT00133198
- Testing
- Pramipexole
- Where
- 44 sites in United States
- Volunteers
- 345 people
- Sponsor
- Boehringer Ingelheim
Idiopathic Restless Legs Syndrome
Phase 3 Open-label Extension Trial With Rotigotine in Idiopathic Restless Legs Syndrome Subjects
This is a multicenter, open-label trial to assess safety and tolerability of rotigotine in subjects with idiopathic Restless Legs Syndrome (RLS), administered at an optimal dose for up to 1 year in subjects who previously…
- Trial name
- NCT00498108
- Testing
- Rotigotine
- Where
- Germany
- Volunteers
- 341 people
- Sponsor
- UCB Pharma
Restless Legs Syndrome (RLS)
Post-marketing Study of Gabapentin Enacarbil to Evaluate the Effect in Restless Leg Syndrome (RLS) Patients With Moderate Renal Impairment
To evaluate the safety, efficacy and pharmacokinetics of gabapentin enacarbil in moderate to severe primary RLS patients with moderate renal impairment and to confirm dosage and administration in such population.
- Trial name
- NCT01981941
- Testing
- Gabapentin enacarbil
- Where
- 5 sites in Japan
- Volunteers
- 19 people
- Sponsor
- Astellas Pharma Inc
Restless Legs Syndrome
Dose Escalating Study of Rotigotine in Pediatric Subjects With Restless Legs Syndrome
This was a multicenter, open-label, dose-escalation, Phase 2A study with multiple administrations of the rotigotine transdermal system.
- Trial name
- NCT01495793
- Testing
- Rotigotine
- Where
- 12 sites in United States
- Volunteers
- 42 people
- Sponsor
- UCB BIOSCIENCES, Inc.
Restless Legs Syndrome
Noninvasive Peripheral Nerve Stimulation for Medication-Refractory Primary RLS (The RESTFUL Study)
Multi-center, prospective double-blind randomized controlled pivotal study of noninvasive peripheral nerve stimulation (NPNS) with the NTX100 Neuromodulation System for patients with medication-refractory moderate-severe primary…
- Trial name
- NCT04874155
- Testing
- NTX100 Neuromodulation System - Active, NTX100 Neuromodulation System - Open-Label
- Where
- 7 sites in United States
- Volunteers
- 133 people
- Sponsor
- Noctrix Health, Inc.
Restless Legs Syndrome
Four Different Transdermal Doses of Rotigotine in Subjects With Idiopathic Restless Legs Syndrome
Subjects who meet the diagnosis of idiopathic restless legs syndrome (RLS) based on the 4 cardinal clinical features according to the International Restless Legs Syndrome Study Group (IRLSSG) are allowed to enroll in this trial.
- Trial name
- NCT00135993
- Testing
- Rotigotine
- Where
- United States
- Volunteers
- 811 people
- Sponsor
- UCB Pharma
RLS
An Efficacy and Safety Evaluation of HORIZANT in Adolescents With Moderate-to-Severe Primary RLS
The primary objective of the trial is to evaluate the efficacy of HORIZANT 300 mg and 600 mg, compared to placebo, at 12 weeks of treatment, for the treatment of Restless Legs Syndrome (RLS) in adolescents (13 to 17 years of age)…
- Trial name
- RLS (NCT02560766)
- Testing
- HORIZANT 300 mg, HORIZANT 600 mg
- Where
- 12 sites in United States
- Volunteers
- 132 people
- Sponsor
- XenoPort, Inc.
Restless Legs Syndrome
Drug Drug Interaction Study With Gabapentin Enacarbil and Morphine
This double-blind study will evaluate the pharmacokinetics of a single dose of morphine or gabapentin derived from gabapentin enacarbil (GEn) after administration of morphine and GEn alone and in combination as well as the…
- Trial name
- NCT01476124
- Testing
- GEn 600 mg, Morphine
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- XenoPort, Inc.
Restless Legs Syndrome
Long-term Open-label Trial in Idiopathic Restless Legs Syndrome (RLS)
This is a multi-center, open-label extension trial conducted at the same European sites that participated in trial SP 709 (NCT00243217).
- Trial name
- NCT00498186
- Testing
- Rotigotine
- Where
- 24 sites in Austria, Germany and 1 more
- Volunteers
- 295 people
- Sponsor
- UCB Pharma